-
Je něco špatně v tomto záznamu ?
Drug compliance in patients with systemic scleroderma
L. Hromadkova, T. Soukup, E. Cermakova, J. Vlcek,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1997-01-01 do 2017-12-31
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-01-01 do 2017-12-31
- MeSH
- adherence k farmakoterapii * MeSH
- adherence pacienta MeSH
- chronická nemoc MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- průřezové studie MeSH
- průzkumy a dotazníky MeSH
- revmatologie metody normy MeSH
- senioři MeSH
- systémová sklerodermie farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Although drug compliance is a crucial component of treatment effectiveness in chronic diseases, it has never been evaluated in patients with systemic scleroderma. Therefore, the aim of this descriptive study was to determine the drug compliance rate in systemic scleroderma patients and to identify risk factors for noncompliance in these patients. A cross-sectional observational study was conducted. All patients with systemic scleroderma (n = 41) who visited a rheumatic center and signed an informed consent form were included. Data were obtained during structured interviews with patients and from medical records. The Compliance Questionnaire Rheumatology (CQR) was used to determine patient compliance. The relationships between compliance rate and demographic and clinical characteristics were examined. The mean CQR score was 75 %. Based on a dichotomous rating, only 42 % of the patients achieved a satisfactory compliance rate (≥80 %). No relationships between various demographic and clinical characteristics and CQR score expressed as continuous or dichotomous variables were found. This study represents the first evaluation of drug compliance in patients with systemic scleroderma. Many noncompliant patients were identified, but no common risk factors for noncompliance were discovered. The reasons for noncompliance seem to depend on the personal features of the patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024359
- 003
- CZ-PrNML
- 005
- 20130708103054.0
- 007
- ta
- 008
- 130703s2012 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10067-012-2050-0 $2 doi
- 035 __
- $a (PubMed)22875701
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Hromadkova, Lucie $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, Hradec Kralove 500 05, Czech Republic. lucie.hromadkova@faf.cuni.cz
- 245 10
- $a Drug compliance in patients with systemic scleroderma / $c L. Hromadkova, T. Soukup, E. Cermakova, J. Vlcek,
- 520 9_
- $a Although drug compliance is a crucial component of treatment effectiveness in chronic diseases, it has never been evaluated in patients with systemic scleroderma. Therefore, the aim of this descriptive study was to determine the drug compliance rate in systemic scleroderma patients and to identify risk factors for noncompliance in these patients. A cross-sectional observational study was conducted. All patients with systemic scleroderma (n = 41) who visited a rheumatic center and signed an informed consent form were included. Data were obtained during structured interviews with patients and from medical records. The Compliance Questionnaire Rheumatology (CQR) was used to determine patient compliance. The relationships between compliance rate and demographic and clinical characteristics were examined. The mean CQR score was 75 %. Based on a dichotomous rating, only 42 % of the patients achieved a satisfactory compliance rate (≥80 %). No relationships between various demographic and clinical characteristics and CQR score expressed as continuous or dichotomous variables were found. This study represents the first evaluation of drug compliance in patients with systemic scleroderma. Many noncompliant patients were identified, but no common risk factors for noncompliance were discovered. The reasons for noncompliance seem to depend on the personal features of the patients.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a adherence k farmakoterapii $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a adherence pacienta $7 D010349
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a revmatologie $x metody $x normy $7 D012219
- 650 _2
- $a systémová sklerodermie $x farmakoterapie $7 D012595
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Soukup, Tomas $u -
- 700 1_
- $a Cermakova, Eva $u -
- 700 1_
- $a Vlcek, Jiri $u -
- 773 0_
- $w MED00001162 $t Clinical rheumatology $x 1434-9949 $g Roč. 31, č. 11 (2012), s. 1577-83
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22875701 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20130708103515 $b ABA008
- 999 __
- $a ok $b bmc $g 988039 $s 822739
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 31 $c 11 $d 1577-83 $i 1434-9949 $m Clinical rheumatology $n Clin Rheumatol $x MED00001162
- LZP __
- $a Pubmed-20130703